Colleen L Wood1, Scott A Clements2, Kim McFann3, Robert Slover4, John F Thomas1,3, R Paul Wadwa4. 1. 1 Department of Pediatrics, Children's Hospital Colorado , Aurora, Colorado. 2. 2 Department of Pediatrics, University of Utah , Salt Lake City, Utah. 3. 3 Colorado School of Public Health , Aurora, Colorado. 4. 4 Barbara Davis Center for Diabetes, University of Colorado School of Medicine , Aurora, Colorado.
Abstract
BACKGROUND: The American Diabetes Association (ADA) recommends that children with type 1 diabetes (T1D) see a multidisciplinary team and have hemoglobin A1c (A1C) levels measured every 3 months. Patients in rural areas may not follow guidelines because of limited specialty care access. We hypothesized that videoconferencing would result in equivalent A1C compared with in-person visits and increased compliance with ADA recommendations. MATERIALS AND METHODS: The Barbara Davis Center (BDC) (Aurora, CO) telemedicine program provides diabetes care to pediatric patients in Casper and Cheyenne, WY, via remote consultation with annual in-person visits. Over 27 months, 70 patients were consented, and 54 patients completed 1 year in the study. RESULTS: Patients were 70% male, with a mean age of 12.1 ± 4.1 years and T1D duration of 5.4 ± 4.1 years. There was no significant change between baseline and 1-year A1C levels for patients with data at both time points. Patients saw diabetes specialists an average of 2.0 ± 1.3 times per year in the year prior to starting telemedicine and 2.9 ± 1.3 times (P < 0.0001) in the year after starting telemedicine. Patients and families missed significantly less school and work time to attend appointments. CONCLUSIONS: Our study suggests telemedicine is equivalent to in-person visits to maintain A1C, whereas families increase the number of visits in line with ADA recommendations. Patients and families miss less school and work. Decreased financial burden and increased access may improve overall diabetes care and compliance for rural patients. Further study is needed to detect long-term differences in complications screenings and the financial impact of telemedicine on pediatric diabetes care.
BACKGROUND: The American Diabetes Association (ADA) recommends that children with type 1 diabetes (T1D) see a multidisciplinary team and have hemoglobin A1c (A1C) levels measured every 3 months. Patients in rural areas may not follow guidelines because of limited specialty care access. We hypothesized that videoconferencing would result in equivalent A1C compared with in-person visits and increased compliance with ADA recommendations. MATERIALS AND METHODS: The Barbara Davis Center (BDC) (Aurora, CO) telemedicine program provides diabetes care to pediatric patients in Casper and Cheyenne, WY, via remote consultation with annual in-person visits. Over 27 months, 70 patients were consented, and 54 patients completed 1 year in the study. RESULTS:Patients were 70% male, with a mean age of 12.1 ± 4.1 years and T1D duration of 5.4 ± 4.1 years. There was no significant change between baseline and 1-year A1C levels for patients with data at both time points. Patients saw diabetes specialists an average of 2.0 ± 1.3 times per year in the year prior to starting telemedicine and 2.9 ± 1.3 times (P < 0.0001) in the year after starting telemedicine. Patients and families missed significantly less school and work time to attend appointments. CONCLUSIONS: Our study suggests telemedicine is equivalent to in-person visits to maintain A1C, whereas families increase the number of visits in line with ADA recommendations. Patients and families miss less school and work. Decreased financial burden and increased access may improve overall diabetes care and compliance for rural patients. Further study is needed to detect long-term differences in complications screenings and the financial impact of telemedicine on pediatric diabetes care.
Authors: Stephanie S Crossen; James P Marcin; Lihong Qi; Hadley S Sauers-Ford; Allison M Reggiardo; Shelby T Chen; Victoria A Tran; Nicole S Glaser Journal: Diabetes Technol Ther Date: 2019-09-18 Impact factor: 6.118
Authors: Jennifer K Raymond; Cari L Berget; Kimberly A Driscoll; Kaitlin Ketchum; Cynthia Cain; John F Fred Thomas Journal: Diabetes Technol Ther Date: 2016-05-19 Impact factor: 6.118
Authors: Matthew F Bouchonville; Margaret M Paul; John Billings; Jessica B Kirk; Sanjeev Arora Journal: Curr Diab Rep Date: 2016-10 Impact factor: 4.810
Authors: Sarah C Haynes; James P Marcin; Parul Dayal; Daniel J Tancredi; Stephanie Crossen Journal: J Telemed Telecare Date: 2020-11-23 Impact factor: 6.184
Authors: Moshe Phillip; Richard M Bergenstal; Kelly L Close; Thomas Danne; Satish K Garg; Lutz Heinemann; Irl B Hirsch; Boris P Kovatchev; Lori M Laffel; Viswanathan Mohan; Christopher G Parkin; Tadej Battelino Journal: Diabetes Technol Ther Date: 2020-09-28 Impact factor: 6.118
Authors: Parul Dayal; Celia H Chang; William S Benko; Aaron M Ulmer; Stephanie S Crossen; Brad H Pollock; Jeffrey S Hoch; Jamie L Kissee; Leslie Warner; James P Marcin Journal: Neurol Clin Pract Date: 2019-08